DOCSLIB.ORG

Sulfotransferase 1A3 (SULT1A3)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sulfotransferase 1A3 (SULT1A3) A Dissertation entitled Functional Genomic Studies On The Genetic Polymorphisms Of The Human Cytosolic Sulfotransferase 1A3 (SULT1A3) by Ahsan Falah Hasan Bairam Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Experimental Therapeutics ________________________________________ Dr. Ming-Cheh Liu, Committee Chair ________________________________________ Dr. Ezdihar Hassoun, Committee Member ________________________________________ Dr. Zahoor Shah, Committee Member ________________________________________ Dr. Caren Steinmiller, Committee Member ________________________________________ Dr. Amanda Bryant-Friedrich, Dean College of Graduate Studies The University of Toledo May 2018 Copyright 2018, Ahsan Falah Hasan Bairam This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of Functional Genomic Studies On The Genetic Polymorphisms Of The Human Cytosolic Sulfotransferase 1A3 (SULT1A3) by Ahsan Falah Hasan Bairam Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Experimental Therapeutics (Pharmacology/Toxicology) The University of Toledo May 2018 Abstract Previous studies have demonstrated the involvement of sulfoconjugation in the metabolism of catecholamines and serotonin (5-HT), as well as a wide range of xenobiotics including drugs. The study presented in this dissertation aimed to clarify the effects of coding single nucleotide polymorphisms (cSNPs) of the human SULT1A3 and SULT1A4 genes on the enzymatic characteristics of the sulfation of catecholamines, 5- HT, and selected drugs by SULT1A3 allozymes. Following a comprehensive search of different SULT1A3 and SULT1A4 genotypes, thirteen non-synonymous (missense) cSNPs of SULT1A3/SULT1A4 were identified. cDNAs encoding the corresponding SULT1A3 allozymes, packaged in pGEX-2T vector were generated by site-directed mutagenesis. Recombinant SULT1A3 allozymes were bacterially expressed and affinity-purified. iii Purified SULT1A3 allozymes were found to exhibit differential sulfating activities toward dopamine (DA), epinephrine (EP), norepinephrine (NE), 5-HT, acetaminophen (APAP), morphine, tapentadol, O-desmethyl tramadol (O-DMT), phenylephrine, and salbutamol, in comparison to the wild-type enzyme. Kinetic analyses further demonstrated differences in substrate affinity (as reflected by Km) and catalytic ativity (as reflected by Vmax) of different SULT1A3 allozymes. Collectively, the findings made provided useful information relevant to the differential metabolism of above-mentioned endogenous and xenobiotic compounds. Such information may eventually shed light on the correlation of particular SULT1A3/SULT1A4 genotypes to neuropathological disorders associated with abnormal levels of the monoamines that act as substrates for SULT1A3. Furthermore, these results obtained may in the future aid in designing personalized regimens of relevant drugs in order to optimize their efficacy and mitigate their adverse effects for individuals with distinct SULT1A3/SULT1A4 genotypes. iv Acknowledgements I would like to express my appreciation and sincere thanks to Dr. Ming-Cheh Liu for being a wonderful advisor, who has always been available for help, excellent guidance, and support. I attribute the level of my doctorate degree to his encouragement, and without him this thesis would not have been completed or written. I would also like to thank my committee members: Dr. Ezdihar Hassoun, Dr. Zahoor Shah, and Dr. Caren Steinmiller for their time, encouragement and insightful comments. I owe my deepest gratitude to my wife and my brother, who greatly supported me and my aspirations and dreams. To all my lab mates, especially, Dr. Katsuhisa Kurogi, thank you for listening and supporting me through this entire process. v Table of Contents Abstract .............................................................................................................................. iii Acknowledgements ..............................................................................................................v Table of Contents ............................................................................................................... vi List of Tables…. ............................................................................................................... xii List of Figures .................................................................................................................. xiv List of Abbreviations ...................................................................................................... xvii List of Symbols ................................................................................................................ xix 1. Introduction........................................................ ..............................................................1 1.1 Overview of Metabolism ..................................................................................1 1.2 Phases of Metabolism .......................................................................................2 1.2.1. Phase I Reactions ...................................................................2 1.2.2. Phase II Reactions..................................................................3 1.2.3. Phase III transporters.............................................................4 1.3. Sulfoconjugation...............................................................................................4 1.4. Sulfotransferases...............................................................................................6 1.4.1. SULT1....................................................................................9 1.4.2. SULT2..................................................................................11 1.4.3. SULT4..................................................................................12 1.4.4. SULT6.................................................................................13 vi 1.5. Genetic variations...........................................................................................13 1.6. SULT1A3........................................................................................................17 1.6.1. Role of human SULT1A3 in the sulfation of endogenous Substrates......................................................................................18 1.6.2. Role of SULT1A3 in the sulfation of xenobiotics...............19 1.6.3. Role of SULT1A3 in the sulfation of food compounds.......20 1.6.4. Pathophysiological association and etiological role of SULT1A3.......................................................................................20 2. Materials and Methods ...................................................................................................24 2.1. Materials.........................................................................................................24 2.2. Methods...........................................................................................................25 2.2.1. Database search....................................................................25 2.2.2. Generation of SULT1A3 cDNAs coding for SULT1A3 allozymes.......................................................................................26 2.2.3. Expression and purification of recombinant SULT1A3 allozymes.......................................................................................34 2.2.4. Analysis of differential sulfating activities of SULT1A3 allozymes toward endogenous and exogenous compounds...........36 2.2.5. Analysis of differential sulfating activities of SULT1A3 allozymes toward xenobiotics........................................................37 2.2.6. Statistical analysis................................................................37 3. Sulfation of Catecholamines and Serotonin by SULT1A3 Allozymes.........................38 3.1. Introduction.....................................................................................................40 vii 3.2. Materials and Methods....................................................................................42 3.2.1. Materials..............................................................................42 3.2.2. Methods................................................................................43 3.2.2.1. Database search.....................................................43 3.2.2.2. Generation, expression, and purification of SULT1A3 allozymes.........................................................43 3.2.2.3. Enzymatic assay....................................................44 3.2.2.4. Statistical analysis.................................................44 3.3. Results.............................................................................................................45 3.3.1. Analysis of human SULT1A3 and SULT1A4 single nucleotide polymorphisms.............................................................45 3.3.2. Expression and purification of recombinant human SULT1A3 allozymes.....................................................................48 3.3.3. Enzymatic characterization of the SULT1A3 allozymes....48 3.3.4. Kinetic Analyses..................................................................55 3.4. Discussion.......................................................................................................61 4.
Load more

Recommended publications
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • Gene Expression Profiles in Testis of Pigs with Extreme High and Low
    BMC Genomics BioMed Central Research article Open Access Gene expression profiles in testis of pigs with extreme high and low levels of androstenone Maren Moe*1,2, Theo Meuwissen2,3, Sigbjørn Lien2,3, Christian Bendixen4, Xuefei Wang4, Lene Nagstrup Conley4, Ingunn Berget3,5, Håvard Tajet1,2 and Eli Grindflek1,3 Address: 1The Norwegian Pig Breeders Association (NORSVIN), Hamar, Norway., 2Department of Animal and Aquacultural Sciences, Norwegian University of Life Sciences, Ås, Norway., 3Centre for Integrative Genetics (CIGENE), Norwegian University of Life Sciences, Ås, Norway., 4Faculty of Agricultural Sciences, University of Aarhus, Tjele, Denmark. and 5MATFORSK, Osloveien 1, Ås, Norway. Email: Maren Moe* - [email protected]; Theo Meuwissen - [email protected]; Sigbjørn Lien - [email protected]; Christian Bendixen - [email protected]; Xuefei Wang - [email protected]; Lene Nagstrup Conley - [email protected]; Ingunn Berget - [email protected]; Håvard Tajet - [email protected]; Eli Grindflek - [email protected] * Corresponding author Published: 7 November 2007 Received: 3 July 2007 Accepted: 7 November 2007 BMC Genomics 2007, 8:405 doi:10.1186/1471-2164-8-405 This article is available from: http://www.biomedcentral.com/1471-2164/8/405 © 2007 Moe et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Boar taint is a major obstacle when using uncastrated male pigs for swine production. One of the main compounds causing this taint is androstenone, a pheromone produced in porcine testis.
    [Show full text]
  • 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 SULT2B1 Purified Mouse Monoclonal Antibody (Mab) Catalog # AM8716b Specification SULT2B1 - Product Information Application WB,E Primary Accession O00204 Reactivity Human Predicted Human Host Mouse Clonality monoclonal Isotype IgG1,κ Calculated MW 41308 SULT2B1 - Additional Information Gene ID 6820 Other Names Sulfotransferase family cytosolic 2B member 1, ST2B1, Sulfotransferase 2B1, All lanes : Anti-SULT2B1 at 1:2000 dilution 2.8.2.2, Alcohol sulfotransferase, Lane 1: MCF-7 whole cell lysate Lane 2: Hydroxysteroid sulfotransferase 2, MDA-MB-468 whole cell lysate SULT2B1, HSST2 Lysates/proteins at 20 µg per lane. Secondary Goat Anti-mouse IgG, (H+L), Target/Specificity Peroxidase conjugated at 1/10000 dilution. This antibody is generated from a mouse Predicted band size : 41 kDa immunized with a reconbinant protein from Blocking/Dilution buffer: 5% NFDM/TBST. human. Dilution WB~~1:8000 Format Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS. Storage Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. Precautions SULT2B1 is for research use only and not for use in diagnostic or therapeutic Anti-SULT2B1 at 1:8000 dilution + MCF-7 procedures. whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-mouse IgG, Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 (H+L), Peroxidase conjugated at 1/10000 SULT2B1 - Protein Information dilution.
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened.
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • The Transition from Primary Colorectal Cancer to Isolated Peritoneal Malignancy
    medRxiv preprint doi: https://doi.org/10.1101/2020.02.24.20027318; this version posted February 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with a hypermutant, hypermethylated state Sally Hallam1, Joanne Stockton1, Claire Bryer1, Celina Whalley1, Valerie Pestinger1, Haney Youssef1, Andrew D Beggs1 1 = Surgical Research Laboratory, Institute of Cancer & Genomic Science, University of Birmingham, B15 2TT. Correspondence to: Andrew Beggs, [email protected] KEYWORDS: Colorectal cancer, peritoneal metastasis ABBREVIATIONS: Colorectal cancer (CRC), Colorectal peritoneal metastasis (CPM), Cytoreductive surgery and heated intraperitoneal chemotherapy (CRS & HIPEC), Disease free survival (DFS), Differentially methylated regions (DMR), Overall survival (OS), TableFormalin fixed paraffin embedded (FFPE), Hepatocellular carcinoma (HCC) ARTICLE CATEGORY: Research article NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.02.24.20027318; this version posted February 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . NOVELTY AND IMPACT: Colorectal peritoneal metastasis (CPM) are associated with limited and variable survival despite patient selection using known prognostic factors and optimal currently available treatments.
    [Show full text]
  • SULT1A3 Rabbit Pab
    Leader in Biomolecular Solutions for Life Science SULT1A3 Rabbit pAb Catalog No.: A12357 Basic Information Background Catalog No. Sulfotransferase enzymes catalyze the sulfate conjugation of many hormones, A12357 neurotransmitters, drugs, and xenobiotic compounds. These cytosolic enzymes are different in their tissue distributions and substrate specificities. The gene structure Observed MW (number and length of exons) is similar among family members. This gene encodes a 34kDa phenol sulfotransferase with thermolabile enzyme activity. Four sulfotransferase genes are located on the p arm of chromosome 16; this gene and SULT1A4 arose from a Calculated MW segmental duplication. This gene is the most centromeric of the four sulfotransferase 34kDa genes. Read-through transcription exists between this gene and the upstream SLX1A (SLX1 structure-specific endonuclease subunit homolog A) gene that encodes a protein Category containing GIY-YIG domains. Primary antibody Applications WB,IHC,IF Cross-Reactivity Human, Mouse, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 6818 P0DMM9 IHC 1:50 - 1:100 Immunogen 1:50 - 1:100 IF Recombinant fusion protein containing a sequence corresponding to amino acids 1-100 of human SULT1A3 (NP_808220.1). Synonyms SULT1A3;HAST;HAST3;M-PST;ST1A3;ST1A3/ST1A4;ST1A5;STM;TL-PST Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using SULT1A3 antibody (A12357) at 1:3000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution.
    [Show full text]
  • Systematic Evaluation of Genes and Genetic Variants Associated with Type 1 Diabetes Susceptibility
    Systematic Evaluation of Genes and Genetic Variants Associated with Type 1 Diabetes Susceptibility This information is current as Ramesh Ram, Munish Mehta, Quang T. Nguyen, Irma of October 7, 2021. Larma, Bernhard O. Boehm, Flemming Pociot, Patrick Concannon and Grant Morahan J Immunol 2016; 196:3043-3053; Prepublished online 24 February 2016; doi: 10.4049/jimmunol.1502056 http://www.jimmunol.org/content/196/7/3043 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2016/02/19/jimmunol.150205 Material 6.DCSupplemental http://www.jimmunol.org/ References This article cites 44 articles, 5 of which you can access for free at: http://www.jimmunol.org/content/196/7/3043.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on October 7, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Systematic Evaluation of Genes and Genetic Variants Associated with Type 1 Diabetes Susceptibility Ramesh Ram,*,† Munish Mehta,*,† Quang T.
    [Show full text]
  • Integrated Mrnaseq and Micrornaseq Data Analysis for Grade III Gliomas
    7468 MOLECULAR MEDICINE REPORTS 16: 7468-7478, 2017 Integrated mRNAseq and microRNAseq data analysis for grade III gliomas JUNQIANG DAI1*, ZHITONG BING2*, YINIAN ZHANG1, QIAO LI1, LIANG NIU1, WENTAO LIANG1, GUOQIANG YUAN3, LEI DUAN1, HANG YIN1 and YAWEN PAN1,3 1Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, Gansu 730030; 2Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000; 3Institute of Neurology, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China Received August 10, 2016; Accepted July 6, 2017 DOI: 10.3892/mmr.2017.7545 Abstract. The World Health Organization classification distin- represent 10% of primary brain tumors (2), which can infil- guishes four grades for gliomas. Grade III gliomas, which trate the surrounding brain parenchyma. Using standard are brain malignant brain tumors with variable biological therapeutic protocols, patients with malignant glioma have behavior and propensity, have been not widely investigated. different pathological appearances and clinical outcomes. The objective of the present study was to identify specific gene Treatments include surgery, radiation therapy, and chemo- modules and valuable hubs associated with gliomagenesis and therapy, however, there is no specialized treatment available. molecular signatures to assist in determining grade III glioma There are insufficient molecular targets relevant in the choice prognosis. mRNAseq and micro (mi)RNAseq data were of therapy, and their role in clinical trials requires validation. used to construct a co-expression network of gliomas using Novel therapeutic methods based on the specific mechanism weight gene co-expression network analysis, and revealed of high grade glioma carcinogenesis are required to improve the prognostic molecular signature of grade III gliomas.
    [Show full text]
  • Widespread Signals of Convergent Adaptation to High Altitude in Asia and America
    bioRxiv preprint doi: https://doi.org/10.1101/002816; this version posted September 26, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Widespread signals of convergent adaptation to high altitude in Asia and America Matthieu Foll 1,2,3,*, Oscar E. Gaggiotti 4,5, Josephine T. Daub 1,2, Alexandra Vatsiou 5 and Laurent Excoffier 1,2 1 CMPG, Institute oF Ecology and Evolution, University oF Berne, Berne, 3012, Switzerland 2 Swiss Institute oF BioinFormatics, Lausanne, 1015, Switzerland 3 Present address: School oF LiFe Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, 1015, Switzerland 4 School oF Biology, Scottish Oceans Institute, University oF St Andrews, St Andrews, FiFe, KY16 8LB, UK 5 Laboratoire d'Ecologie Alpine (LECA), UMR 5553 CNRS-Université de Grenoble, Grenoble, France * Corresponding author: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/002816; this version posted September 26, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Living at high-altitude is one oF the most diFFicult challenges that humans had to cope with during their evolution. Whereas several genomic studies have revealed some oF the genetic bases oF adaptations in Tibetan, Andean and Ethiopian populations, relatively little evidence oF convergent evolution to altitude in diFFerent continents has accumulated.
    [Show full text]
  • 1 Mucosal Effects of Tenofovir 1% Gel 1 Florian Hladik1,2,5*, Adam
    1 Mucosal effects of tenofovir 1% gel 2 Florian Hladik1,2,5*, Adam Burgener8,9, Lamar Ballweber5, Raphael Gottardo4,5,6, Lucia Vojtech1, 3 Slim Fourati7, James Y. Dai4,6, Mark J. Cameron7, Johanna Strobl5, Sean M. Hughes1, Craig 4 Hoesley10, Philip Andrew12, Sherri Johnson12, Jeanna Piper13, David R. Friend14, T. Blake Ball8,9, 5 Ross D. Cranston11,16, Kenneth H. Mayer15, M. Juliana McElrath2,3,5 & Ian McGowan11,16 6 Departments of 1Obstetrics and Gynecology, 2Medicine, 3Global Health, 4Biostatistics, University 7 of Washington, Seattle, USA; 5Vaccine and Infectious Disease Division, 6Public Health Sciences 8 Division, Fred Hutchinson Cancer Research Center, Seattle, USA; 7Vaccine and Gene Therapy 9 Institute-Florida, Port St. Lucie, USA; 8Department of Medical Microbiology, University of 10 Manitoba, Winnipeg, Canada; 9National HIV and Retrovirology Laboratories, Public Health 11 Agency of Canada; 10University of Alabama, Birmingham, USA; 11University of Pittsburgh 12 School of Medicine, Pittsburgh, USA; 12FHI 360, Durham, USA; 13Division of AIDS, NIAID, NIH, 13 Bethesda, USA; 14CONRAD, Eastern Virginia Medical School, Arlington, USA; 15Fenway Health, 14 Beth Israel Deaconess Hospital and Harvard Medical School, Boston, USA; 16Microbicide Trials 15 Network, Magee-Women’s Research Institute, Pittsburgh, USA. 16 Adam Burgener and Lamar Ballweber contributed equally to this work. 17 *Corresponding author E-mail: [email protected] 18 Address reprint requests to Florian Hladik at [email protected] or Ian McGowan at 19 [email protected]. 20 Abstract: 150 words. Main text (without Methods): 2,603 words. Methods: 3,953 words 1 21 ABSTRACT 22 Tenofovir gel is being evaluated for vaginal and rectal pre-exposure prophylaxis against HIV 23 transmission.
    [Show full text]